Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)

NCT00561080 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

759

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of : Herpes-Zoster

Interventions

BIOLOGICAL: Zostavax

Sponsor

Merck Sharp & Dohme LLC